earnings
confidence high
sentiment positive
materiality 0.75
Paysign Q2 revenue $19.08M (+33%), net income $1.39M (+99%), raises FY2025 guidance
Paysign, Inc.
2025-Q2 EPS
reported $0.07
vs consensus $0.04
▲ beat
(+96.1%)
- Q2 revenue $19.08M (+33.1% YoY), net income $1.39M (+99.1%), diluted EPS $0.02; Adj. EBITDA $4.51M (+101.8%), $0.08 per share.
- Pharma patient affordability revenue surged 189.9% to 40.6% of total; added 7 net programs, now 97 active.
- Added 123 net plasma centers in Q2, exiting with 607; plasma revenue down 4.7% due to industry oversupply.
- FY2025 guidance raised: revenue $76.5-78.5M, net income $6-7M ($0.10-0.12 diluted EPS), Adj. EBITDA $18-20M.
- Q3 2025 guidance: revenue $19.5-20.5M, gross margin ~59%, Adj. EBITDA $4.5-5.0M.